Some new Yescarta data | GILD Message Board Posts

Gilead Sciences, Inc.

  GILD website

  •  Registered Members of Investor Village:
    Please make sure you are signed in to your Investor Village account to enjoy the full benefits of our service and avoid the MediaPass paywall. If the MediaPass offer page is blocking you, click the light blue "No thanks, take me back" link on the middle right side of the form to get to our home page where you can sign in by entering your Investor Village User Name and Password. 

     MediaPass subscribers: Please make sure you are logged in to your MediaPass subscription to bypass the paywall. You can do this by clicking the light blue "Already have a MediaPass account? Login here" link on the middle left side of the subscription offer form and then entering the email address and password you used when you first signed up with MediaPass.  

    For assistance call 888-222-7309 or email admin@investorvillage.com

GILD   /  Message Board  /  Read Message

 

 






Keyword
Subject
Between
and
Rec'd By
Authored By
Minimum Recs
  
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board
Msg  11884 of 12024  at  6/11/2019 9:23:07 AM  by

captsolo


 In response to msg 11883 by  mymorningsong
view thread

Re: Some new Yescarta data

If JUNO's Liso-Cel is approved it will be 12 months from now. I don't think it comes close to matching up with ZUMA 1 (or other ZUMA trials with CR as high as 80%), and FDA surely knows the same, so I say Liso-Cel isn't worthy of approval - especially since the CR is lower than ZUMA 1 (over 250 patients including real life).

Why would a doctor / hospital ask for it over Yescarta? CR rate of 46% is NOT better than Yescarta in real world.

JUNO missed the boat IMO.

Kymriah's manufacturing issues got so bad that FDA would not let them sell it commercially - but could only give it away.

GILD on the other hand has had zero manufacturing issues with their CAR T.

Yescarta will have 4 years of no deaths by the time Liso-Cel (just old JCAR15?) https://www.fiercebiotech.com/r-d/juno-ditches-lead-car-t-program-following-patient-deaths


     e-mail to a friend      printer-friendly     add to library      
| More
Recs: 0     Views: 212
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board

Replies
Msg # Subject Author Recs Date Posted
11885 Re: Some new Yescarta data mymorningsong 1 6/11/2019 10:16:57 AM






About Us  •  Contact Us  •  Follow Us on Twitter  •  Members Directory  •  Help Center  •  Advertise
Not a member yet? What are you waiting for? Create Account
Want to contribute? Support InvestorVillage by donating
© 2003-2019 Investorvillage.com. All rights reserved. User Agreement
   
Financial Market Data provided by
.


Loading...